Vaxart Growth, Revenue, Number of Employees and Funding
Estimated Revenue & Financials
- Vaxart's estimated revenue is currently $4.2M per year.
- Vaxart received $18.4M in venture funding in January 2015.
- Vaxart's estimated revenue per employee is $126030
- Vaxart's total funding is $58.6M.
- Vaxart has 33 Employees.
- Vaxart grew their employee count by -15% last year.
- Vaxart currently has 1 job openings.
|Sean Tucker||Founder/Chief Scientific Officer/Dir|
|John Harland||Vice President Financial Planning and Administration|
|Keith Gottlieb||Associate Director, Clinical Immunology|
|Patti Orozco Cronin||Sr. Director of Clinical Operations at Vaxart Inc.|
|Jaya Nair||Director Of Manufacturing Operations|
|David Ingamells||Vice President of Manufacturing|
|David Taylor||Chief Medical Officer|
|Eric Wenzel||Director, Clinical Development|
|Brant Biehn||Senior VP Commercial Operations|
|Uday Patel||Vice President Regulatory Affairs|
What Is Vaxart?
Vaxart is a clinical-stage company developing tablet vaccines based on its proprietary oral vaccine platform. The lead programs are prophylactic oral vaccines for seasonal influenza, RSV and norovirus, as well as a therapeutic vaccine for HPV types 16 and 18. Vaxart vaccines are convenient room temperature-stable tablets that are easy to administer, and that eliminate risk of needle-stick injury and medical waste associated with injectable vaccines. The company is listed on the NASDAQ exchange under ticker nymbol VXRT.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Advanced Cell D...||$25.7M||178||8%|
|Full Spectrum A...||$6M||42||5%|
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--. Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant ...
Stock analysts at Brookline Capital Management assumed coverage on shares of Vaxart (NASDAQ:VXRT) in a research note issued on ...
Vaxart (NASDAQ:VXRT) has been given a $2.00 target price by HC Wainwright in a research note issued on Wednesday, August 21st, ...
|2007-11-16||$3.3M||A||Quantum Technology Partners, Life Science Angels||Article|
|2010-03-05||$12.5M||B||Care Capital of Princeton NJ||Article|
Vaxart Executive Hires
|2014-05-09||John M. Harland||CFO||Article|
|2016-02-10||Samir Singh||SVP corporate development and strategy.||Article|
|2018-04-20||Brant Biehn||SVP Commercial Operations||Article|
|2018-05-02||David Taylor||Chief Medical Officer||Article|